Bausch Health
As of the edition of 20 October 2026, Bausch Health runs 171 drugs, 154 of them marketed; it is on route A at 8 targets and on route B at 23 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 10 company names in this family.
- Aton Pharma Inc: acquired in 2010; successor ICN Pharmaceuticals
- Biovail Laboratories International Srl: renamed in 2012
- Valeant International Barbados Srl: merged in 2012; successor Valeant International Bermuda
- BAUSCH & LOMB PHARMA HOLDINGS CORP.: renamed in 2018
- Valeant International Bermuda: merged in 2025
- Valeant Pharmaceuticals North America Llc: renamed in 2025
- Valeant Pharmaceuticals: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 154 |
| Active | 6 |
| Went quiet | 9 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 171 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fluorouracil | none listed | 2 |
| Metformin | none listed | 4 |
| Ribavirin | none listed | 1 |
| Prednisolone | none listed | 6 |
| Budesonide | Ends 2029 (exclusivity) | 5 |
| Rifampin | none listed | 0 |
| Naltrexone | none listed | 6 |
| Zoledronic acid anhydrous | none listed | 4 |
| Hydrocortisone | none listed | 5 |
| Bupropion | none listed | 2 |
| Albuterol | none listed | 2 |
| Hydrochlorothiazide | none listed | 4 |
| Metronidazole | none listed | 0 |
| Tramadol | none listed | 3 |
| Triamcinolone acetonide | none listed | 3 |
| Minocycline | none listed | 0 |
| Levodopa | none listed | 4 |
| Tretinoin | none listed | 3 |
| Phenylephrine | none listed | 6 |
| Isoniazid | none listed | 0 |
| Rifaximin | Ends 2027 (patent) | 0 |
| Imiquimod | none listed | 2 |
| Timolol | none listed | 5 |
| Atropine | none listed | 12 |
| Fenofibrate | none listed | 3 |
A route B row is one company at one target. 129 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 8 targets, route B at 23 targets.
All 31 rows on route A or B
In the product31 company-target rows on route A or B; 28 are not shown here, and no score is.
See all 31 targets where Bausch Health needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Eye: 45 trials led
- Skin and connective tissue: 21 trials led
- Digestive system: 17 trials led